Presentation is loading. Please wait.

Presentation is loading. Please wait.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

Published byАлексей Устименко Modified over 5 years ago

Similar presentations

Presentation on theme: "Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter."— Presentation transcript:

1 Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter 2017. bDMARDs, biological disease modifying antirheumatic drugs. Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter 2017. bDMARDs, biological disease modifying antirheumatic drugs. Sytske Anne Bergstra et al. Ann Rheum Dis 2018;77: ©2018 by BMJ Publishing Group Ltd and European League Against Rheumatism

Download ppt "Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter."

Similar presentations

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71:700-706 doi:10.1136/annrheumdis-2011-200358.

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.
Figure 3 Simplified EULAR and GRAPPA

Figure 3 Simplified EULAR and GRAPPA
Figure 2 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
(A) Lequesne index and quadriceps strength of patients with knee OA

(A) Lequesne index and quadriceps strength of patients with knee OA
Figure 1 Simplified EULAR and GRAPPA

Figure 1 Simplified EULAR and GRAPPA
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.

Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Status of premarket submissions to FDA (data source: U. S

Status of premarket submissions to FDA (data source: U. S
Child poverty and infant mortality in the Organisation for Economic Co-operation and Development (OECD) countries. Child poverty and infant mortality in.

Child poverty and infant mortality in the Organisation for Economic Co-operation and Development (OECD) countries. Child poverty and infant mortality in.
Nelson-Aalen plots comparing nbDMARD and TNFi cohorts for each outcome

Nelson-Aalen plots comparing nbDMARD and TNFi cohorts for each outcome
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.
Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Similar presentations

Ads by Google